Is GPR146 really the receptor for proinsulin C-peptide?


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 07 2020
Historique:
received: 20 02 2020
revised: 16 04 2020
accepted: 18 04 2020
pubmed: 2 5 2020
medline: 3 6 2021
entrez: 2 5 2020
Statut: ppublish

Résumé

Proinsulin C-peptide has previously been proposed to interact with a G-protein coupled receptor (GPCR), specifically the orphan receptor GPR146. To investigate the potential of C-peptide in treating complications of diabetes, such as kidney damage, it is necessary to understand its mode of action. We used CHO-K1 cells expressing human GPR146 to study human and murine C-peptide in dynamic mass redistribution and GPCR β-arrestin assays, as well as with fluorescence confocal microscopy. Neither assay revealed any significant intracellular response to C-peptide at concentrations of up to 33 µM. We observed no internalisation of C-peptide by fluorescence microscopy. Our results do not support GPR146 as the receptor for C-peptide, but suggest that further investigations of the mode of action of C-peptide should be undertaken.

Identifiants

pubmed: 32354568
pii: S0960-894X(20)30308-5
doi: 10.1016/j.bmcl.2020.127208
pii:
doi:

Substances chimiques

C-Peptide 0
GPR146 protein, human 0
Receptors, G-Protein-Coupled 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

127208

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Lina Lindfors (L)

Dept. of Chemistry - BMC, Uppsala University, SE-751 23 Uppsala, Sweden.

Linda Sundström (L)

Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, 431 50 Mölndal, Sweden.

Linda Fröderberg Roth (L)

Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, 431 50 Mölndal, Sweden.

Johan Meuller (J)

Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, 431 50 Mölndal, Sweden.

Shalini Andersson (S)

Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, 431 50 Mölndal, Sweden.

Jan Kihlberg (J)

Dept. of Chemistry - BMC, Uppsala University, SE-751 23 Uppsala, Sweden. Electronic address: jan.kihlberg@kemi.uu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH